Cited by 163HIV-related health complications and treatmentsAdipokines, Inflammation, and Metabolic DiseasesRegulation of Appetite and Obesity

Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy.

Lee, Jennifer H., Chan, Jean L., Sourlas, Epaminondas, Raptopoulos, Vassilios, Mantzoros, Christos S.·2006·The Journal of Clinical Endocrinology & Metabolism

Abstract

CONTEXT: Highly active antiretroviral therapy (HAART) for HIV-1 infection has been associated with a metabolic syndrome characterized by insulin resistance, hyperlipidemia, and redistribution of body fat (lipodystrophy). A subset of patients with predominant lipoatrophy has low levels of the adipocyte-secreted hormone leptin. OBJECTIVE: The objective of the study was to assess whether administration of recombinant methionyl human leptin (r-metHuLeptin) improves insulin resistance and other metabolic abnormalities in HIV+ leptin-deficient subjects with HAART-induced lipoatrophy. DESIGN, SETTING, PATIENTS, AND INTERVENTION: We conducted a randomized, placebo-controlled, double-blinded, crossover study from 2002 to 2004 in seven HIV+ men with HAART-induced lipoatrophy, serum leptin level less than 3 ng/ml, and fasting triglyceride level greater than 300 mg/dl, who were administered placebo for 2 months before or after administration of r-metHuLeptin at physiological doses for an additional 2 months. MAIN OUTCOME MEASURES: Insulin resistance, lipid levels, inflammatory markers, body composition, and HIV control were measured. RESULTS: Compared with placebo, r-metHuLeptin therapy improved fasting insulin levels, insulin resistance (as expressed by the homeostasis model assessment index and an insulin suppression test), and high-density lipoprotein. Body weight and fat mass decreased on r-metHuLeptin, mainly due to a decrease in truncal fat but not peripheral fat or lean body mass. r-metHuLeptin was well tolerated, and HIV control was not adversely affected. CONCLUSIONS: r-metHuLeptin replacement at physiological doses in HIV+ leptin-deficient patients with HAART-induced lipoatrophy improves insulin resistance, high-density lipoprotein, and truncal fat mass. Future larger and more long-term studies in HAART-induced lipoatrophy, including patients with more severe metabolic abnormalities, are warranted to evaluate the physiological and potentially therapeutic role of r-metHuLeptin for this condition and to fully clarify the underlying mechanisms of action.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2005-1545

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Leptin concentrations are positively correlated with the amount of body fat.

    “Leptin concentrations are positively correlated with the amount of body fat (4-10).”

    From Leptin in humans: lessons from translational research (2009) · cites this paper as [10]

  • Leptin administration in replacement doses significantly improved glycemia, dyslipidemia, and hepatic steatosis in lipoatrophic, hypoleptinemic patients with severe insulin resistance.

    “It has been shown that leptin administration in replacement doses significantly improved glycemia, dyslipidemia, and hepatic steatosis in lipoatrophic, hypoleptinemic patients with severe insulin resistance.”

    From Leptin in humans: lessons from translational research (2009) · cites this paper as [10]

  • Leptin administration improved lipidemia and insulin resistance in HIV-positive patients with partial lipoatrophy.

    “It also improved lipidemia and insulin resistance in HIVpositive patients with partial lipoatrophy (10,(22)(23)(24)(25)(26).”

    From Leptin in humans: lessons from translational research (2009) · cites this paper as [10]

  • r-metHuLeptin therapy in replacement doses improved insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by highly active antiretroviral therapy.

    “r-metHuLeptin therapy in replacement doses improved insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy (10).”

    From Leptin in humans: lessons from translational research (2009) · cites this paper as [10]

  • The finding of body fat loss with metreleptin has also been observed in studies assessing metreleptin in humans with severe lipodystrophy and other conditions associated with relative leptin deficiency.

    “This fi nding also has been observed in studies assessing the effect of metreleptin on metabolic parameters in humans with severe lipodystrophy and other conditions associated with relative leptin de fi ciency (39 -41).”

    From Leptin is an effective treatment for hypothalamic amenorrhea (2011) · cites this paper as [40]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Lee, J. H., Chan, J. L., Sourlas, E., Raptopoulos, V., & Mantzoros, C. S.
Affiliations
  • Division of Endocrinology, Diabetes, and Metabolism (J.H.L., J.L.C., C.S.M.) Boston, Massachusetts 02215
  • Boston University (US)
  • Beth Israel Deaconess Medical Center (US)
Corresponding author
Mantzoros, Christos S.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2006-07-01
Volume
91
Issue
7
Pages
2605-2611
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2118921194
Cited by
163
References
48
Citations by year
2024: 4 · 2023: 5 · 2022: 4 · 2021: 2 · 2020: 2 · 2019: 2 · 2018: 3 · 2017: 7 · 2016: 7 · 2015: 8 · 2014: 20 · 2013: 12 · 2012: 12
FWCI
15.70
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • U.S. Public Health Service (R0-158785)
  • National Institute of Diabetes and Digestive and Kidney Diseases (5T32-DK-07516-18, T32DK007516)
  • National Center for Research Resources (M01RR001032, K23RR018860)
Topics
  • Health Sciences › Medicine › Emergency Medicine › HIV-related health complications and treatments
  • Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
leptin replacement therapy, metabolic syndrome, insulin resistance, HIV infection, leptin deficiency, hypertriglyceridemia, HDL cholesterol, truncal fat, body composition, HIV viral load
MeSH terms
Acquired Immunodeficiency Syndrome, Adolescent, Adult, Body Composition, Double-Blind Method, Humans, Insulin, Insulin Resistance, Lipids, Lipoproteins, HDL, Male, Placebos, Recombinant Proteins, HIV-1, Interleukin-6, Body Mass Index, Cross-Over Studies, Leptin, Antiretroviral Therapy, Highly Active, Metabolic Syndrome, HIV-Associated Lipodystrophy Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review